Do analysts prefer BNR or CAPR?

Capricor Therapeutics has a consensus target price of $30.25, suggesting a potential upside of 241.04%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capricor Therapeutics 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27

Do analysts prefer BNR or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend BNR or CCCC?

C4 Therapeutics has a consensus target price of $8.50, indicating a potential upside of 183.33%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 C4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts rate BNR or EDIT?

Editas Medicine has a consensus price target of $5.83, suggesting a potential upside of 132.40%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Editas Medicine 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Do analysts prefer ALT or BNR?

Altimmune currently has a consensus target price of $14.33, indicating a potential upside of 638.83%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Burning Rock Biotech (BNR) Competitors

$13.24 +0.57 (+4.50%)

Closing price 04:00 PM Eastern

Extended Trading

$13.40 +0.15 (+1.17%)

As of 04:10 PM Eastern

Compare

BNR vs. CAPR, AVTE, CCCC, EDIT, and ALT

Should you buy Burning Rock Biotech stock or one of its competitors? Burning Rock Biotech's main competitors and comparable companies include Capricor Therapeutics (CAPR), Aerovate Therapeutics (AVTE), C4 Therapeutics (CCCC), Editas Medicine (EDIT), and Altimmune (ALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Burning Rock Biotech compare to Capricor Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Capricor Therapeutics had 14 more articles in the media than Burning Rock Biotech. MarketBeat recorded 15 mentions for Capricor Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.82 beat Capricor Therapeutics' score of 0.24 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Capricor Therapeutics	Neutral

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Burning Rock Biotech has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Capricor Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
Capricor Therapeutics	N/A	-56.60%	-43.97%

Capricor Therapeutics has a consensus target price of $30.25, suggesting a potential upside of 241.04%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Burning Rock Biotech has higher revenue and earnings than Capricor Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.73	-$7.92M	-$0.87	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.45	N/A

Summary

Burning Rock Biotech beats Capricor Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Burning Rock Biotech compare to Aerovate Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Burning Rock Biotech has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

30.0% of Burning Rock Biotech shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 1 articles in the media. Burning Rock Biotech's average media sentiment score of 1.82 beat Aerovate Therapeutics' score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Aerovate Therapeutics	Neutral

Burning Rock Biotech has higher revenue and earnings than Aerovate Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.73	-$7.92M	-$0.87	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aerovate Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

Burning Rock Biotech beats Aerovate Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Burning Rock Biotech compare to C4 Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Burning Rock Biotech has a net margin of -13.60% compared to C4 Therapeutics' net margin of -282.22%. Burning Rock Biotech's return on equity of -12.98% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
C4 Therapeutics	-282.22%	-37.71%	-26.42%

C4 Therapeutics has a consensus target price of $8.50, indicating a potential upside of 183.33%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Burning Rock Biotech has higher revenue and earnings than C4 Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.73	-$7.92M	-$0.87	N/A
C4 Therapeutics	$35.95M	10.96	-$104.99M	-$0.72	N/A

In the previous week, C4 Therapeutics had 17 more articles in the media than Burning Rock Biotech. MarketBeat recorded 18 mentions for C4 Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.82 beat C4 Therapeutics' score of 0.37 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
C4 Therapeutics	Neutral

Burning Rock Biotech has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market.

Summary

C4 Therapeutics beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Editas Medicine?

Burning Rock Biotech (NASDAQ:BNR) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Burning Rock Biotech has a net margin of -13.60% compared to Editas Medicine's net margin of -144.95%. Burning Rock Biotech's return on equity of -12.98% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
Editas Medicine	-144.95%	-158.18%	-37.80%

Editas Medicine has a consensus price target of $5.83, suggesting a potential upside of 132.40%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Burning Rock Biotech has higher revenue and earnings than Editas Medicine. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.73	-$7.92M	-$0.87	N/A
Editas Medicine	$49.83M	7.74	-$160.06M	-$0.62	N/A

In the previous week, Editas Medicine had 12 more articles in the media than Burning Rock Biotech. MarketBeat recorded 13 mentions for Editas Medicine and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.82 beat Editas Medicine's score of 0.15 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Editas Medicine	Neutral

Burning Rock Biotech has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summary

Editas Medicine beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Altimmune?

Altimmune (NASDAQ:ALT) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Altimmune currently has a consensus target price of $14.33, indicating a potential upside of 638.83%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Altimmune had 5 more articles in the media than Burning Rock Biotech. MarketBeat recorded 6 mentions for Altimmune and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.82 beat Altimmune's score of 0.38 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Altimmune	Neutral
Burning Rock Biotech	Very Positive

Altimmune has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	N/A	-31.41%	-26.96%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

Altimmune has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than Altimmune. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	9,434.22	-$88.09M	-$0.78	N/A
Burning Rock Biotech	$77.16M	1.73	-$7.92M	-$0.87	N/A

Summary

Altimmune beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$139.29M	$4.17B	$7.90B	$12.22B
Dividend Yield	N/A	3.64%	2.47%	4.43%
P/E Ratio	-15.22	25.50	35.37	30.85
Price / Sales	1.81	16.47	8.48	5.83
Price / Cash	N/A	26.87	22.22	22.66
Price / Book	1.82	4.22	4.44	3.79
Net Income	-$7.92M	-$22.76M	$3.50B	$390.16M
7 Day Performance	3.20%	-1.11%	-0.96%	-1.09%
1 Month Performance	-14.53%	-6.79%	-4.06%	-6.17%
1 Year Performance	10.89%	1.71%	2.05%	-5.70%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	1.1045 of 5 stars	$13.24 +4.5%	N/A	+6.2%	$139.29M	$77.16M	N/A	667	Positive News Upcoming Earnings Gap Up
CAPR Capricor Therapeutics	2.96 of 5 stars	$8.24 +13.8%	$30.25 +267.1%	+59.5%	$420.93M	$22.27M	N/A	231	Trending News Earnings Report Analyst Upgrade Gap Up
AVTE Aerovate Therapeutics	N/A	$13.93 -0.9%	N/A	+69.7%	$403.76M	N/A	N/A	20	High Trading Volume
CCCC C4 Therapeutics	1.9855 of 5 stars	$3.21 flat	$9.33 +190.8%	+28.2%	$394.91M	$35.95M	N/A	104	Earnings Report Analyst Revision
EDIT Editas Medicine	2.3638 of 5 stars	$2.60 +1.2%	$5.83 +124.4%	-0.4%	$394.70M	$40.52M	N/A	87	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. CAPR, AVTE, CCCC, EDIT, and ALT

How does Burning Rock Biotech compare to Capricor Therapeutics?

Summary

How does Burning Rock Biotech compare to Aerovate Therapeutics?

Summary

How does Burning Rock Biotech compare to C4 Therapeutics?

Summary

How does Burning Rock Biotech compare to Editas Medicine?

Summary

How does Burning Rock Biotech compare to Altimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. CAPR, AVTE, CCCC, EDIT, and ALT

How does Burning Rock Biotech compare to Capricor Therapeutics?

Does the media refer more to BNR or CAPR?

Do institutionals & insiders hold more shares of BNR or CAPR?

Which has more risk & volatility, BNR or CAPR?

Is BNR or CAPR more profitable?

Do analysts prefer BNR or CAPR?

Which has preferable valuation & earnings, BNR or CAPR?

Summary

How does Burning Rock Biotech compare to Aerovate Therapeutics?

Which has more volatility and risk, BNR or AVTE?

Do institutionals & insiders hold more shares of BNR or AVTE?

Does the media refer more to BNR or AVTE?

Which has better valuation and earnings, BNR or AVTE?

Do analysts prefer BNR or AVTE?

Is BNR or AVTE more profitable?

Summary

How does Burning Rock Biotech compare to C4 Therapeutics?

Do institutionals and insiders believe in BNR or CCCC?

Is BNR or CCCC more profitable?

Do analysts recommend BNR or CCCC?

Which has higher earnings & valuation, BNR or CCCC?

Does the media refer more to BNR or CCCC?

Which has more volatility and risk, BNR or CCCC?

Summary

How does Burning Rock Biotech compare to Editas Medicine?

Do insiders and institutionals have more ownership in BNR or EDIT?

Is BNR or EDIT more profitable?

Do analysts rate BNR or EDIT?

Which has better valuation & earnings, BNR or EDIT?

Does the media favor BNR or EDIT?

Which has more risk and volatility, BNR or EDIT?

Summary

How does Burning Rock Biotech compare to Altimmune?

Do analysts prefer ALT or BNR?

Do insiders & institutionals believe in ALT or BNR?

Does the media refer more to ALT or BNR?

Is ALT or BNR more profitable?

Which has more risk and volatility, ALT or BNR?

Which has stronger valuation and earnings, ALT or BNR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools